跳至主要内容
临床试验/NCT07300917
NCT07300917招募中不适用

Efficacy and Safety of a 1726-nm Sebaceous-Targeting Diode Laser for the Treatment of Fordyce Spots of the Lips: A Prospective Pilot Study

Venus Research Center2 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2025年11月1日最近更新:

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
20
试验地点
2
主要终点
Percentage Reduction in Fordyce Spot Count

研究概览

简要总结

Fordyce spots are benign ectopic sebaceous glands commonly affecting the lips and vermilion border, often causing cosmetic concern. This prospective pilot study evaluates the efficacy and safety of a 1726-nm sebaceous-targeting diode laser (Accure®) for the cosmetic treatment of Fordyce spots of the lips. Participants will receive 2-3 laser sessions and will be followed for 6-12 months to assess clinical improvement, patient satisfaction, and safety outcomes.

详细描述

This is a prospective, single-arm pilot study evaluating the use of a 1726-nm diode laser that selectively targets sebaceous glands via lipid absorption. The device employs a temperature-guided, multi-pulse delivery system with continuous cooling and is FDA-cleared for the treatment of inflammatory acne.

Eligible participants with clinically evident Fordyce spots of the lips and/or vermilion border will receive 2-3 treatment sessions spaced four weeks apart. Outcomes include lesion count reduction, global aesthetic improvement scores, patient satisfaction, and safety assessments. Follow-up visits will occur at Weeks 4, 8, 12, 24. To better characterize durability and recurrence, participants will be invited (optional) to return for an additional observational follow-up at Month 12 (±4 weeks), without any additional study treatment. Participants who do not attend the Month-12 visit will be considered complete after the Week-24 assessment and will not be contacted further beyond routine clinical care. All analyses of efficacy and safety will be based on assessments through Week 24, with Month-12 data summarized descriptively as extended follow-up where available.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age ≥18 years
  • Clinically evident Fordyce spots involving: Upper and/or lower lips and/or vermilion border
  • Cosmetic concern related to Fordyce spots
  • Willingness to comply with study procedures and follow-up visits
  • Ability to provide written informed consent

排除标准

  • Active herpes labialis at the treatment site
  • History of frequent HSV reactivation without willingness for antiviral prophylaxis
  • Isotretinoin use within the preceding 6 months
  • Active inflammatory or infectious lip/mucosal disease (e.g., lichen planus, cheilitis, candidiasis)
  • Known tendency for keloid or hypertrophic scarring Pregnancy or lactation
  • Immunosuppression or uncontrolled systemic illness
  • Previous treatment of Fordyce spots in the target area within 3 months

结局指标

主要结局

Percentage Reduction in Fordyce Spot Count

时间窗: Baseline to Week 12

The percentage change from baseline in the number of visible Fordyce spots on the lips and vermilion border, assessed using standardized clinical photographs and lesion counting within predefined grid areas.

次要结局

  • Treatment Safety and Tolerability(Baseline to Month 6)
  • Investigator Global Improvement Assessment (IGA)(Baseline to Week 12)
  • Patient Global Aesthetic Improvement Scale (Patient-GAIS)(Baseline to Week 12)
  • Patient Satisfaction Score(Week 12)

研究者

发起方
Venus Research Center
申办方类型
Other
责任方
Principal Investigator
主要研究者

Mahmoud Rageh

Dermatologist

Venus Research Center

研究点 (2)

Loading locations...

相似试验